MedPath

A phase IV, open-label, multi-center follow-up study to determine the persistence of tick-borne encephalitis (TBE)-specific antibody responses among children and adolescents previously immunized against TBE. - M48P3E1

Conditions
o medical condition, healthy volunteers will be recruited.(In this study the status of antibody titers against tick borne encephalitis will be investigated in healthy subjects who have received their primary vaccination in a parent trial in 2006.)
Registration Number
EUCTR2009-010145-31-DE
Lead Sponsor
ovartis Vaccines and Diagnostics GmbH & Co. KG
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Healthy M48P3 study subjects with parental or legal guardian informed consent (health status as determined by review of medical history and physical examination and in the clinical judgment of the investigator)

Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•Subjects who did not receive complete schedule of primary vaccination in M48P3.
•Subjects enrolled in other investigational studies at the same time and within the last three months
•Subjects with any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath